Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

被引：0
|
作者：
T M Beer
D C Smith
A Hussain
M Alonso
J Wang
M Giurescu
K Roth
Y Wang
机构：
[1] Knight Cancer Institute,
[2] Oregon Health & Science University,undefined
[3] University of Michigan Health System,undefined
[4] University of Maryland Medical Center,undefined
[5] Marlene and Stewart Greenebaum Cancer Center,undefined
[6] Private Hospital of Córdoba,undefined
[7] University of Nebraska Medical Center,undefined
[8] Bayer HealthCare Pharmaceuticals,undefined
[9] Astellas Pharma Global Development,undefined
来源：
British Journal of Cancer | 2012年 / 107卷
关键词：
clinical trial; phase II; epothilones; prednisone; prostatic neoplasms;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：808 / 813
页数：5
相关论文
共 50 条
  • [1] Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    Beer, T. M.
    Smith, D. C.
    Hussain, A.
    Alonso, M.
    Wang, J.
    Giurescu, M.
    Roth, K.
    Wang, Y.
    BRITISH JOURNAL OF CANCER, 2012, 107 (05) : 808 - 813
  • [2] Phase II study of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer (CRPC)
    Beer, T. M.
    Smith, D. C.
    Hussain, A.
    Alonso, M.
    Wang, J.
    Giurescu, M.
    Wang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer (CRPC)
    De Jager, R. L.
    Roman, L.
    Lopatkin, N.
    Karlov, P.
    Breitz, H.
    Earhart, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study
    Aggarwal, Rahul
    Bryce, Alan
    Ryan, Charles J.
    Harzstark, Andrea
    Derleth, Christina
    Kim, Won
    Friedlander, Terence
    Lin, Amy M.
    Rodvelt-Bagchi, Tammy
    Dhawan, Mallika
    Zhang, Li
    Lee, Mina
    Siebeneck, Eric
    Hough, Jeffrey
    Small, Eric J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (04)
  • [5] A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
    Sridhar, Srikala S.
    Canil, Christina M.
    Chi, Kim N.
    Hotte, Sebastien J.
    Ernst, Scott
    Wang, Lisa
    Chen, Eric X.
    Juhasz, Agnes
    Yen, Yun
    Murray, Peter
    Zwiebel, James A.
    Moore, Malcolm J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 927 - 933
  • [6] A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
    Srikala S. Sridhar
    Christina M. Canil
    Kim N. Chi
    Sebastien J. Hotte
    Scott Ernst
    Lisa Wang
    Eric X. Chen
    Agnes Juhasz
    Yun Yen
    Peter Murray
    James A. Zwiebel
    Malcolm J. Moore
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 927 - 933
  • [7] Ixabepilone, Mitoxantrone, and Prednisone for Metastatic Castration-Resistant Prostate Cancer After Docetaxel-Based Therapy A Phase 2 Study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    Harzstark, Andrea L.
    Rosenberg, Jonathan E.
    Weinberg, Vivian K.
    Sharib, Jeremy
    Ryan, Charles J.
    Smith, David C.
    Pagliaro, Lance C.
    Beer, Tomasz M.
    Liu, Glenn
    Small, Eric J.
    CANCER, 2011, 117 (11) : 2419 - 2425
  • [8] Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: A phase II study of the DOD Prostate Cancer Clinical Trials Consortium
    Small, E.
    Harzstark, A.
    Weinberg, V. K.
    Smith, D. C.
    Mathew, P.
    Beer, T.
    Liu, G.
    Sharib, J.
    Rosenberg, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    Rosenberg, Jonathan E.
    Ryan, Charles J.
    Weinberg, Vivian K.
    Smith, David C.
    Hussain, Maha
    Beer, Tomasz M.
    Ryan, Christopher W.
    Mathew, Paul
    Pagliaro, Lance C.
    Harzstark, Andrea L.
    Sharib, Jeremy
    Small, Eric J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (17) : 2772 - 2778
  • [10] A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study
    J E Ward
    T Karrison
    G Chatta
    M Hussain
    D Shevrin
    R Z Szmulewitz
    P H O'Donnell
    W M Stadler
    E M Posadas
    Prostate Cancer and Prostatic Diseases, 2012, 15 : 87 - 92
12345